Status:

COMPLETED

Roflumilast in Non-CF Bronchiectasis Study (2019)

Lead Sponsor:

The University of Hong Kong

Conditions:

Non-cystic Fibrosis Bronchiectasis

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This is a single-arm, open label, Phase II study of 12-week use of Roflumilast in stable-state non-cystic fibrosis bronchiectasis subjects. Bronchiectasis refers to a suppurative lung condition chara...

Detailed Description

In a 4-week crossover study in 38 patients with COPD, roflumilast 500μg daily significantly reduced sputum absolute neutrophil count, IL-8 and neutrophil elastase compared with placebo treatment. Inte...

Eligibility Criteria

Inclusion

  • Aged 18 years or above, male or female.
  • Never-smokers or those who have smoked less than 100 cigarettes in their lifetime.
  • Confirmed diagnosis of non-CF bronchiectasis based on high-resolution computed tomography (HRCT) scan.
  • Significant sputum production (≥ 10 ml per day).
  • In stable-state bronchiectasis with no change in regular medications (e.g. inhaled steroid, macrolide) or exacerbations in the past 3 months.
  • Written informed consent obtained.

Exclusion

  • Eversmokers (≥ 100 cigarettes in their lifetime).
  • Known chronic obstructive pulmonary disease or asthma.
  • Moderate to severe liver impairment (Child-Pugh B or C).
  • Known psychiatric illness with increased suicidal risks.
  • Body-mass index below 18 kg/m2.
  • Concomitant use of strong cytochrome P450 inducers (e.g. rifampicin, phenobarbital, carbamazepine, phenytoin).
  • Patients who are hypersensitive to roflumilast or its constituents.
  • Pregnant or lactating women.

Key Trial Info

Start Date :

November 12 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 30 2024

Estimated Enrollment :

42 Patients enrolled

Trial Details

Trial ID

NCT04322929

Start Date

November 12 2020

End Date

November 30 2024

Last Update

December 9 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Queen Mary Hospital

Hong Kong, Hong Kong

Roflumilast in Non-CF Bronchiectasis Study (2019) | DecenTrialz